Viridian inks $185M financing, hires three Magenta executives as CEO Scott Myers exits
Stephen Mahoney joined Viridian Therapeutics as CEO on Monday, with the former Magenta Therapeutics president marking the autoimmune biotech’s third chief executive in less than 12 months.
Mahoney replaces Scott Myers, who had led AMAG Pharmaceuticals before signing on as Viridian CEO in February when he filled in for Jonathan Violin. Sunday was Myers’ last day after an “involuntary termination,” per a Monday morning SEC filing. Shares of Viridian $VRDN were up almost 9% after the opening bell.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.